COVID-19 and acute lymphoblastic leukemias of children and adolescents: First recommendations of the Leukemia committee of the French Society for the fight against Cancers and Leukemias in children and adolescents (SFCE)

André Baruchel; Yves Bertrand; Nicolas Boissel; Benoit Brethon; Stéphane Ducassou; Virginie Gandemer; Carine Halfon-Domenech; Thierry Leblanc; Guy Leverger; Gérard Michel; Arnaud Petit; Anne-France Ray-Lunven; Pierre-Simon Rohrlich; Pascale Schneider; Nicolas Sirvent; Marion Strullu; SFCE Leukemia Committee

doi:10.1016/j.bulcan.2020.04.003

COVID-19 and acute lymphoblastic leukemias of children and adolescents: First recommendations of the Leukemia committee of the French Society for the fight against Cancers and Leukemias in children and adolescents (SFCE)

Bull Cancer. 2020 Jun;107(6):629-632. doi: 10.1016/j.bulcan.2020.04.003. Epub 2020 Apr 30.

Authors

André Baruchel¹, Yves Bertrand², Nicolas Boissel³, Benoit Brethon⁴, Stéphane Ducassou⁵, Virginie Gandemer⁶, Carine Halfon-Domenech², Thierry Leblanc⁴, Guy Leverger⁷, Gérard Michel⁸, Arnaud Petit⁷, Anne-France Ray-Lunven⁴, Pierre-Simon Rohrlich⁹, Pascale Schneider¹⁰, Nicolas Sirvent¹¹, Marion Strullu⁴; SFCE Leukemia Committee

Affiliations

¹ Hôpital Universitaire Robert-Debré AP-HP, Université de Paris, service d'hémato-immunologie pédiatrique, Paris, France. Electronic address: [email protected].
² CHU de Lyon, institut d'hémato-oncologie pédiatrique, Lyon, France.
³ Hôpital Saint-Louis, AP-HP, Université de Paris, unité adolescents et jeunes adultes, Paris, France.
⁴ Hôpital Universitaire Robert-Debré AP-HP, Université de Paris, service d'hémato-immunologie pédiatrique, Paris, France.
⁵ Groupe hospitalier Pellegrin, unité d'hémato-oncologie pédiatrique, Bordeaux, France.
⁶ CHU de Rennes, service d'hémato-oncologie pédiatrique, Rennes, France.
⁷ Hôpital Armand-Trousseau AP-HP, Sorbonne université, service d'hémato-oncologie pédiatrique, Paris, France.
⁸ CHU la Timone, service d'hématologie pédiatrique, Marseille, France.
⁹ CHU l'Archet, service d'hémato-oncologie pédiatrique, Nice, France.
¹⁰ CHU Charles-Nicolle, service d'hématologie pédiatrique, Rouen, France.
¹¹ CHU Arnaud-de-Villeneuve, service d'hématologie et oncologie pédiatrique, Montpellier, France.

Abstract

Since the emergence of the SARS-CoV-2 infection, many recommendations have been made. However, the very nature of acute lymphoblastic leukemias and their treatment in children and adolescents led the Leukemia Committee of the French Society for the fight against cancers and leukemias in children and adolescents (SFCE) to propose more specific recommendations, even if data for this population are still scarce. They may have to evolve according to the rapid evolution of knowledge on COVID-19.

Keywords: Acute lymphoblastic leukemia-children-adolescents; COVID-19; SARS-CoV-2.

Publication types

Practice Guideline

MeSH terms

Adolescent
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Antiviral Agents / pharmacokinetics
Antiviral Agents / therapeutic use
COVID-19
COVID-19 Testing
Child
Clinical Laboratory Techniques
Combined Modality Therapy
Comorbidity
Coronavirus Infections / diagnosis
Coronavirus Infections / epidemiology*
Coronavirus Infections / prevention & control
Disease Management
Down Syndrome / epidemiology
Drug Interactions
Febrile Neutropenia / chemically induced
Febrile Neutropenia / drug therapy
Febrile Neutropenia / prevention & control
Female
Granulocyte Colony-Stimulating Factor / therapeutic use
Hematopoietic Stem Cell Transplantation / adverse effects
Humans
Immunocompromised Host
Male
Pandemics / prevention & control
Pneumonia, Viral / diagnosis
Pneumonia, Viral / epidemiology*
Pneumonia, Viral / prevention & control
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
Recurrence
Remission Induction
Risk
Risk Assessment
Salvage Therapy
Symptom Assessment

Substances

Antiviral Agents
Granulocyte Colony-Stimulating Factor